Targeting MET Exon 14 Skipping Alterations: Has Lung Cancer MET Its Match?

被引：6

作者：

Yap, Timothy A. ^{[1
,2
]}

Popat, Sanjay ^{[1
,3
]}

机构：

[1] Royal Marsden Hosp, London, England

[2] Inst Canc Res, London, England

[3] Imperial Coll London, Natl Heart & Lung Inst, London, England

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期

关键词：

ACQUIRED-RESISTANCE; AMPLIFICATION; INHIBITORS; MUTATIONS; CARCINOMA;

D O I：

10.1016/j.jtho.2016.10.019

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：12 / 14

页数：3

共 50 条

[31] Detection of MET exon 14 skipping mutations in non-small cell lung cancer: overview and community perspective
Subramanian, Janakiraman
Tawfik, Ossama
EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (08) : 877 - 886
[32] MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer
Zheng, Difan
Wang, Rui
Ye, Ting
Yu, Su
Hu, Haichuan
Shen, Xuxia
Li, Yuan
Ji, Hongbin
Sun, Yihua
Chen, Haiquan
ONCOTARGET, 2016, 7 (27) : 41691 - 41702
[33] Novel MET exon 14 skipping analogs characterized in non-small cell lung cancer patients: A case study
Shi, Minke
Ma, Jing
Feng, Meilin
Liang, Lei
Chen, Hongyuan
Wang, Tao
Xie, Zhenghua
CANCER GENETICS, 2021, 256 : 62 - 67
[34] Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management
Veillon, Remi
Sakai, Hiroshi
Le, Xiuning
Felip, Enriqueta
Cortot, Alexis B.
Smit, Egbert F.
Park, Keunchil
Griesinger, Frank
Britschgi, Christian
Wu, Yi-Long
Melosky, Barbara
Baijal, Shobhit
de Castro Jr, Gilberto
Sedova, Michaela
Berghoff, Karin
Otto, Gordon
Paik, Paul K.
CLINICAL LUNG CANCER, 2022, 23 (04) : 320 - 332
[35] Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro
Fujino, Toshio
Kobayashi, Yoshihisa
Suda, Kenichi
Koga, Takamasa
Nishino, Masaya
Ohara, Shuta
Chiba, Masato
Shimoji, Masaki
Tomizawa, Kenji
Takemoto, Toshiki
Mitsudomi, Tetsuya
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : 1753 - 1765
[36] Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping Mutations
Jamme, Philippe
Fernandes, Marie
Copin, Marie-Christine
Descarpentries, Clotilde
Escande, Fabienne
Morabito, Angela
Gregoire, Valerie
Jamme, Matthieu
Baldacci, Simon
Tulasne, David
Kherrouche, Zoulika
Cortot, Alexis B.
JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (05) : 741 - 751
[37] Use of savolitinib as neoadjuvant therapy for non-small cell lung cancer patient with MET exon 14 skipping alterations: A case report
Zhang, Yu
Zhang, Hao
Wang, Hanqing
Zeng, Jingtong
Zhang, Bo
Zhou, Ning
Zu, Lingling
Song, Zuoqing
Wang, Changli
Xu, Song
FRONTIERS IN ONCOLOGY, 2022, 12
[38] Functional Analysis of MET Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
Wang, Feng
Liu, Yang
Qiu, Wanglong
Shum, Elaine
Feng, Monica
Zhao, Dejian
Zheng, Deyou
Borczuk, Alain
Cheng, Haiying
Halmos, Balazs
CANCER RESEARCH, 2022, 82 (07) : 1365 - 1379
[39] Real world experience with MET inhibitors in MET exon 14 skipping mutated non-small cell lung cancer: largest Indian perspective
Batra, Ullas
Singh, Ajay Kumar
Nathany, Shrinidhi
Dewan, Abhinav
Sharma, Mansi
Amrith, B. P.
Mehta, Anurag
Batra, Vanshika
Noronha, Vanita
Prabhash, Kumar
DISCOVER ONCOLOGY, 2025, 16 (01)
[40] Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing
Kim, So Yeon
Yin, Jun
Bohlman, Stephen
Walker, Phillip
Dacic, Sanja
Kim, Chul
Khan, Hina
Liu, Stephen V.
Ma, Patrick C.
Nagasaka, Misako
Reckamp, Karen L.
Abraham, Jim
Uprety, Dipesh
Wang, Feng
Xiu, Joanne
Zhang, Jian
Cheng, Haiying
Halmos, Balazs
JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (09):

← 1 2 3 4 5 →